IONS vs CAI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IONS · Ionis Pharmaceuticals$39.42 ▲ 1.60%
CAI · Caris Life Sciences$25.23 ▼ 3.07%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IONS -43.3%
- CAI +1.7%
Head to head
| Metric | IONS | CAI |
|---|---|---|
| Price | $39.42 | $25.23 |
| Change today | ▲ 1.60% | ▼ 3.07% |
| Market cap | $6.55B | $7.24B |
| Return, 3 months | -30.8% | +7.8% |
| Return, year to date | -50.2% | -6.5% |
| Return, 1 year | -46.4% | -1.5% |
| P/E (TTM) | – | 75.3 |
| P/B | 14.9 | 11.3 |
| P/E percentile vs own 5y | 81st | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -40.7% | +45.4% |
| Net profit growth (YoY) | -192.8% | +99.1% |
| Gross margin | 98.2% | 69.7% |
| Operating margin | -68.0% | 15.5% |
| Net margin | -64.7% | 10.6% |
| Return on equity | -105.5% | 20.1% |
| Analyst target vs. price | +112.8% | +22.9% |
| Analyst buy share | 90% | 75% |
| RSI (14) | 33 | 35 |
| 30-day volatility | 38.0% | 96.1% |
| Max drawdown, 1 year | -55.1% | -53.3% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CAI is the largest of the group by market value.
- CAI has returned the most over the past year.
- CAI is growing revenue fastest.
- CAI keeps the most profit per dollar of sales.
- IONS has been the calmest stock over the last 30 days.